Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial

Bibliographic Details
Title: Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial
Authors: Bourdette, Dennis, Yadav, Vijayshree, Goodman, Andrew, Racke, Michael, Fallis, Robert, Tornatore, Carlo, Goldman, Myla, Kannan, Meena, Sriram, Subramaniam, Berger, Joseph, Cross, Anne, Rammohan, Kottil, Xia, Zongqi, Leist, Thomas, Lynch, Sharon, Klawiter, Eric, Amezcua, Lilyana, Bowen, James, Corboy, John R *, Fox, Robert J, Kister, Ilya, Cutter, Gary R, Morgan, Charity J, Seale, Rebecca, Engebretson, Eric, Gustafson, Tarah, Miller, Aaron E
Source: In The Lancet Neurology July 2023 22(7):568-577
Database: ScienceDirect
More Details
ISSN:14744422
DOI:10.1016/S1474-4422(23)00154-0
Published in:The Lancet Neurology
Language:English